These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 21431323

  • 1. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
    Tong H, Li K, Mei C, Wang H, Chen Z, Jin J.
    Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
    [No Abstract] [Full Text] [Related]

  • 2. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G, Kopp L, Estey E, Wells RJ.
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [Abstract] [Full Text] [Related]

  • 3. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T, Westervelt P, Hess JL.
    Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
    [Abstract] [Full Text] [Related]

  • 4. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
    Strehl S, König M, Boztug H, Cooper BW, Suzukawa K, Zhang SJ, Chen HY, Attarbaschi A, Dworzak MN.
    Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
    [No Abstract] [Full Text] [Related]

  • 5. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M, Sugimoto K, Isobe Y, Oshimi K.
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract] [Full Text] [Related]

  • 6. ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia.
    Kim MJ, Yoon HS, Cho SY, Lee HJ, Suh JT, Lee J, Yoon HJ, Lee WI, Park TS.
    Cancer Genet Cytogenet; 2010 Sep; 201(2):116-21. PubMed ID: 20682396
    [Abstract] [Full Text] [Related]

  • 7. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D, Nasr R, de The H.
    Int J Biochem Cell Biol; 2007 Sep; 39(6):1063-70. PubMed ID: 17468032
    [Abstract] [Full Text] [Related]

  • 8. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P.
    J Biol Regul Homeost Agents; 1999 Sep; 13(4):195-200. PubMed ID: 10703942
    [Abstract] [Full Text] [Related]

  • 9. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK, Gillan E, Quinn JJ, Altman AJ.
    J Pediatr Hematol Oncol; 1998 Sep; 20(6):545-7. PubMed ID: 9856675
    [Abstract] [Full Text] [Related]

  • 10. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D, Mistry AR, Solomon E, Guidez F.
    Cancer Treat Res; 2010 Sep; 145():219-35. PubMed ID: 20306254
    [Abstract] [Full Text] [Related]

  • 11. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
    Yan J, Chen X, Shao J.
    Eur J Haematol; 2013 Nov; 91(5):470-1. PubMed ID: 23869721
    [No Abstract] [Full Text] [Related]

  • 12. Acute promyelocytic leukemia in childhood.
    Gregory J, Feusner J.
    Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
    [Abstract] [Full Text] [Related]

  • 13. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
    Thomas X, Pigneux A, Raffoux E, Huguet F, Caillot D, Fenaux P.
    Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
    [Abstract] [Full Text] [Related]

  • 14. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
    Zhao W, Wang X, Guo W, Qu B, Wang H, Shen Z, Chen Z, Wang Z.
    Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
    [Abstract] [Full Text] [Related]

  • 15. Autophagic degradation of an oncoprotein.
    Bøe SO, Simonsen A.
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [Abstract] [Full Text] [Related]

  • 16. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J.
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract] [Full Text] [Related]

  • 17. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin, Huang MJ, Chang IY, Lin WY, Sheu YT.
    Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
    [Abstract] [Full Text] [Related]

  • 18. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
    Zhang X, Yang L, Qiao Z.
    Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
    [Abstract] [Full Text] [Related]

  • 19. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U.
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [Abstract] [Full Text] [Related]

  • 20. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
    Shen Y, Fu YK, Zhu YM, Lou YJ, Gu ZH, Shi JY, Chen B, Chen C, Zhu HH, Hu J, Zhao WL, Mi JQ, Chen L, Zhu HM, Shen ZX, Jin J, Wang ZY, Li JM, Chen Z, Chen SJ.
    EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.